VeraDermics
VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a patented extended-release oral minoxidil for pattern hair loss in men and women, with three Phase 3 trials underway and patent protection to 2043.
- Company typePublic
- Founded2019
- HeadquartersNew Haven, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What VeraDermics does
VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil formulation designed to treat pattern hair loss (androgenetic alopecia) in men and women. The company's core technology targets the narrow gap between minoxidil's hair-growth efficacy threshold and its cardiac side-effect threshold by maintaining sustained plasma concentrations for 15-24 hours, versus 4-6 hours for immediate-release formulations, while avoiding the concentration spikes associated with cardiovascular adverse events. VeraDermics is currently running three Phase 3 registration-directed trials (Studies 302 and 304 in males and Study 306 in females), with composition-of-matter and formulation patent protection extending to 2043.
The company is pre-revenue and has no approved products, reporting a $70.0 million net loss for full year 2025 driven primarily by $62.1 million in R&D expense. Its future revenue model is expected to rely on prescription pharmaceutical sales of VDPHL01 upon FDA approval, with a planned go-to-market strategy combining specialty dermatology field sales with direct-to-consumer marketing aimed at the large cash-pay aesthetics consumer. VeraDermics is headquartered in New Haven, Connecticut, was incorporated in Delaware in 2019, and completed its IPO on the NYSE under ticker MANE in February 2026, followed by a $414.4 million follow-on offering in April 2026.
VeraDermics targets an addressable market of approximately 80 million Americans with androgenetic alopecia, and sell-side analyst modeling from Jefferies projects approximately $2 billion in peak US sales if VDPHL01 achieves expected penetration.
VeraDermics firmographics
Firmographics- Name
- VeraDermics
- Legal name
- VeraDermics, Inc.
- Website
- https://veradermics.com
- Company type
- Public
- Founded year
- 2019
- Operating status
- Ipo
- Headcount range
- 11–50 employees
- Short description
- VeraDermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a patented extended-release oral minoxidil for pattern hair loss in men and women, with three Phase 3 trials underway and patent protection to 2043.
- Ownership category
- akta.pro rank
VeraDermics industry classification
Industry- Product category
- Dermatology Pharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Clinical Development (Phase I–III Trial Design & Execution) (HLAIALAE)
- akta.pro secondary industry
- Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth) (CRABABAE)
Keywords
Where VeraDermics is headquartered
LocationHeadquarters
- HQ city
- New Haven
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
VeraDermics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Pre-revenue clinical stage: Veradermics is a late clinical-stage biopharmaceutical company with no product revenue. The company reported a net loss of $53.81 million for the twelve months ending September 30, 2025, with zero product revenue. Future revenue model will be based on pharmaceutical product sales of VDPHL01 upon FDA approval, with Jefferies modeling approximately $2 billion in peak adjusted U.S. sales.
Go-to-market motion3 records
Distribution channels2 records
Marketing channels6 records
VeraDermics product offering
Product offeringCore offering
Veradermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil tablet designed specifically for pattern hair loss (androgenetic alopecia) in men and women. The sustained-release formulation maintains therapeutic plasma concentrations for 15-24 hours versus 4-6 hours for immediate-release oral minoxidil, with a release profile designed to avoid cardiac activity threshold spikes. VDPHL01 is currently in three Phase 3 registration-directed clinical trials (Studies 302 and 304 in males, Study 306 in females) and is being positioned as the first FDA-approved oral non-hormonal treatment for pattern hair loss in nearly 30 years.
Product overview
VeraDermics is a single-product-platform late clinical-stage biopharmaceutical company whose offerings are centered on VDPHL01, its lead investigational extended-release oral minoxidil candidate for pattern hair loss, evaluated through three Phase 3 trials (Study 302 in males, Study 304 in males, and Study 306 in females). VDPHL01 is the core asset around which all current clinical and commercial activity is organized, supported by a small portfolio of exploratory pipeline assets in alopecia areata, common warts, and molluscum contagiosum that may be advanced in the future. The company is dermatologist-founded and primarily delivers value through advancing VDPHL01 through FDA registration and commercialization rather than offering a multi-module SaaS-style platform.
Differentiator
Problem solved
Functional benefit
Products and services
- VDPHL01 VDPHL01 is a proprietary, extended-release oral minoxidil tablet designed specifically for pattern hair loss in men and women. The extended-release formulation extends minoxidil plasma exposure to 15-24 hours versus 4-6 hours for immediate-release, while avoiding cardiac threshold spikes. Currently in three Phase 3 clinical trials (Studies 302 and 304 in males, Study 306 in females) with patent protection extending to 2043.
- Alopecia Areata Program Exploratory pipeline asset in alopecia areata developed as part of Veradermics' broader dermatology portfolio beyond VDPHL01, generated from the founders' real-world clinical experience as dermatologists.
- Common Warts Program Exploratory pipeline asset in common warts treatment based on a dissolvable microneedle patch platform; part of Veradermics' broader dermatology portfolio originally developed as the company's lead program.
- Molluscum Contagiosum Program Exploratory pipeline asset in molluscum contagiosum developed as part of Veradermics' broader dermatology portfolio beyond VDPHL01.
Quantifiable outcome
- 30.3 hairs/cm² (once-daily) and 33.0-37.7 hairs/cm² (twice-daily) increase in target area hair count at Month 6 vs. 7.3 hairs/cm² for placebo (p<.0001)
- +5 more outcomes
Companies that use VeraDermics
Customer profileSegments3 records
Ideal customer profiles3 records
VeraDermics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
VeraDermics partnerships and signals
Strategic signalPartnerships
Three partnerships are on record, tiered minor and major.
- Achieve Life SciencesminorVeradermics CEO Reid Waldman, MD was appointed to Achieve Life Sciences' Board of Directors in June 2026, alongside Jeffrey Farrow. The appointment brings Veradermics' CEO expertise in aesthetics and dermatology therapeutics to Achieve's cytisinicline pipeline (smoking cessation NDA and vaping cessation Breakthrough Therapy-designated program).
- J.W. Childs AssociatesmajorJohn W. Childs, chairman of J.W. Childs Associates (private equity firm focusing on life sciences), serves on Veradermics' board of directors. J.W. Childs Associates is an early investor in the company. Mr. Childs also serves on boards of Biohaven Pharmaceuticals, Pyramid Biosciences, OMAX Health, Basin Holdings, and Realm LLC.
- American Academy of DermatologymajorVeradermics presented VDPHL01 data at the AAD Annual Meeting in Denver (March 2026), reaching the dermatology clinical community. Board member Jane Grant-Kels, MD previously served on the Board of Directors of the American Academy of Dermatology.
Scale indicators15 records
Recent moves7 records
Expansion highlights6 records
VeraDermics competitors and assessment
Company assessmentDirect peers
- Dermavant Sciences: Dermatology-focused biopharma with VTAMA (tapinarof) for psoriasis and atopic dermatitis, now part of Organon. Specialty dermatology pipeline and commercial model align directly with Veradermics' planned physician-channel and field-force GTM.
- Sun Pharmaceutical Industries: India-based global generic and specialty pharma that markets Loniten (immediate-release oral minoxidil), the off-label incumbent for pattern hair loss. Direct competitor to VDPHL01 given overlapping active ingredient and prescriber base.
- Revance Therapeutics: Aesthetic dermatology biopharma behind DAXXIFY and the former RHA filler line (sold to Crown Laboratories). Closely comparable aesthetics-focused specialty pharma model with dermatologist field sales force and similar cash-pay consumer dynamics to Veradermics' planned VDPHL01 launch.
- Arcutis Biotherapeutics: Dermatology-focused biopharmaceutical company with approved topical treatments (ZORYVE) for plaque psoriasis and atopic dermatitis, plus pipeline in alopecia areata. Comparable late clinical-to-commercial dermatology specialty model with similar prescriber base and GTM motion.
- Aclaris Therapeutics: Clinical-stage dermatology biopharma developing JAK inhibitors for alopecia areata and other inflammatory skin conditions. Most directly comparable to Veradermics in late-stage dermatology pipeline focus, public-company scale, and single-asset commercial economics.
Broad incumbents
- Galderma Holding AG: Global dermatology specialty company spanning aesthetics, prescription dermatology, and consumer skincare. Comparable prescriber base and aesthetic dermatology channel that Veradermics will rely on for VDPHL01 commercialization.
- Eli Lilly and Company: Global biopharma that signaled a stake of up to 4.9% in Veradermics at IPO. Comparable as a potential strategic acquirer with significant aesthetics/dermatology franchise interest and financial capacity to acquire Veradermics outright post-NDA.
- AbbVie (Allergan Aesthetics): Global biopharma whose Allergan Aesthetics unit (Botox, CoolSculpting, Latisse) dominates aesthetic medicine. Comparable cash-pay aesthetics channel, dermatologist relationships, and potential acquirer profile for Veradermics.
- Pfizer Inc. Global biopharma that markets Rogaine (topical minoxidil), the incumbent OTC/prescription brand in pattern hair loss. Represents the established competitive incumbent VDPHL01 must displace, with massive DTC marketing scale.
- Organon & Co. Global women's health and dermatology specialty company with a portfolio including VTAMA and established dermatology sales infrastructure. Relevant given VDPHL01's female PHL opportunity and potential strategic acquirer profile for Veradermics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
VeraDermics social profiles
Digital presenceVeraDermics financial estimates
Financial estimateRevenue estimate
Valuation estimate
VeraDermics leadership team
Management profileNumber of profiles
Profiles10 records
VeraDermics funding detail
Funding detailFunding overview
Funding rounds7 records
Investors20 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
VeraDermics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about VeraDermics
What does VeraDermics do?
Veradermics is a late clinical-stage biopharmaceutical company developing VDPHL01, a proprietary extended-release oral minoxidil tablet designed specifically for pattern hair loss (androgenetic alopecia) in men and women. The sustained-release formulation maintains therapeutic plasma concentrations for 15-24 hours versus 4-6 hours for immediate-release oral minoxidil, with a release profile designed to avoid cardiac activity threshold spikes. VDPHL01 is currently in three Phase 3 registration-directed clinical trials (Studies 302 and 304 in males, Study 306 in females) and is being positioned as the first FDA-approved oral non-hormonal treatment for pattern hair loss in nearly 30 years.
Is VeraDermics a public or private company?
VeraDermics is a public company. It is classified as public and is currently ipo.
When was VeraDermics founded?
VeraDermics was founded in 2019. It employs 11 to 50 people.
Where is VeraDermics based?
VeraDermics is headquartered in New Haven, United States, in the North America region.
How does VeraDermics make money?
One revenue line is on record: pre-revenue clinical stage.
Who are VeraDermics's main competitors?
Direct peers on record are Dermavant Sciences, Sun Pharmaceutical Industries, Revance Therapeutics, Arcutis Biotherapeutics and Aclaris Therapeutics. Broad incumbents are Galderma Holding AG, Eli Lilly and Company, AbbVie (Allergan Aesthetics), Pfizer Inc. and Organon & Co..
Does VeraDermics have an API?
No public API is recorded for VeraDermics.
What industry is VeraDermics in?
VeraDermics's product category is Dermatology Pharmaceuticals. Its primary akta.pro industry code is HLAIALAE, Clinical Development (Phase I–III Trial Design & Execution), with a secondary code of CRABABAE, Treatments & Scalp Care (Serums, Oils, Anti-dandruff, Growth). Its NAICS code is 325414 and its SIC code is 2834.